ClearPoint Neuro Inc.

Company Overview

Business Model: ClearPoint Neuro, Inc. is a commercial-stage medical device company that develops and commercializes integrated systems for minimally invasive neurosurgical procedures in the brain. The Company's business comprises two integrated components: medical devices for neurosurgical applications and partnerships in the biologics and drug delivery space. Its primary medical device, the ClearPoint system, provides MRI-guided navigation for procedures such as deep brain stimulation, biopsies, laser catheter insertions, and pharmaceutical infusions. The Company has expanded its offerings to include operating room-based neurosurgical devices, such as the SmartFrame OR Stereotactic System and ClearPoint Navigation Software Version 3.0, and the ClearPoint Prism Neuro Laser Therapy System for laser ablation. In 2025, through the acquisition of IRRAS Holdings, Inc., ClearPoint Neuro, Inc. expanded into neurocritical care with the IRRA flow Active Fluid Exchange System, which integrates continuous irrigation, drainage, and real-time intracranial pressure monitoring. The biologics and drug delivery segment provides preclinical development services, clinical trial support, and regulatory consultation to pharmaceutical and biotech partners, leveraging its SmartFlow Neuro cannula for direct brain delivery of gene and cell therapies. The Company's revenue model emphasizes high-margin disposable product sales, with reusable components often sold at lower margins to secure hospital installations and drive recurring revenue.

Market Position: ClearPoint Neuro, Inc. holds a competitive position in the neurosurgical and neurocritical care markets, offering differentiated technologies for MRI-guided interventions, operating room navigation, laser therapy, and active intracranial fluid management. The Company has exclusive global rights to commercialize the ClearPoint Prism Neuro Laser Therapy System for neuro applications. In the biologics and drug delivery space, ClearPoint Neuro, Inc. partners with over 60 pharma/biotech, academic, and contract research organizations, supporting trials for gene and cell therapies targeting various neurological disorders. This segment is identified as potentially the largest opportunity for growth. While the medical device industry is highly competitive with larger, well-established players, ClearPoint Neuro, Inc. differentiates its IRRA flow system through its active fluid exchange capabilities, irrigation and drainage features, and continuous monitoring functionalities.

Recent Strategic Developments:

• Acquisition: Completed the acquisition of IRRAS Holdings, Inc. in November 2025, integrating the IRRA flow active fluid-exchange system into its product portfolio to expand into neurocritical care.
• Financing: Secured a debt financing arrangement with an affiliate of Oberland Capital Management LLC, raising approximately $48.1 million in net proceeds during 2025, and raised approximately $3.3 million in net proceeds from a common stock sale to an affiliate of Oberland Capital Management LLC.
• Facility Expansion: Entered into a lease for a new 30,000 square-foot preclinical research facility, ClearPoint Advanced Laboratories, in San Diego, California, to increase operational capabilities and service capacity for biopharma partners.
• Product Launches & Regulatory Approvals:
  • Received FDA Clearance for ClearPoint Navigation Software Version 3.0 in 2025, enabling operating room navigation and enhanced laser therapy applications.
  • Obtained FDA 510(k) clearance in 2025 for the ClearPoint Prism Neuro Laser Therapy System, expanding compatibility with 1.5T scanners.
  • Achieved European Medical Device Regulation (EU MDR) certification for the SmartFlow Neuro Cannula in 2025.
  • Expanded regulatory approvals for key therapy delivery products in Canada, Hong Kong, and Taiwan in 2025, bringing total international clearances to 34 countries.
  • Launched the SmartFrame OR Stereotactic System in 2024, allowing complete procedures to be performed in the operating room.
  • The SmartFlow Neuro cannula received De Novo marketing authorization in 2024 for intraputaminal administration of eladocagene exuparvovec-tneq for AADC deficiency.
• Partnership Progress: Several pharmaceutical partners advanced through preclinical and clinical review, with over ten receiving expedited U.S. FDA review designations in 2025.

Geographic Footprint: ClearPoint Neuro, Inc.'s operations and primary revenue generation are predominantly in the United States, with headquarters in Solana Beach, California, and manufacturing/R&D facilities in Carlsbad and San Diego, California. The Company also has foreign wholly-owned subsidiaries in the United Kingdom and the EU to support clinical services. Its products have received international clearances in 34 countries worldwide, and the IRRA flow system holds CE mark certification in the European Union.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 61% (2025), 61% (2024)
• Operating Margin: -65.4% (2025)
• Net Margin: -69.1% (2025)

Investment in Growth:

• R&D Expenditure: $13.9 million (37.6% of revenue)
• Capital Expenditures: $0.5 million
• Strategic Investments: The acquisition of IRRAS Holdings, Inc. involved $5.0 million in cash and $17.8 million in equity consideration. The Company also entered into a lease for a new 30,000 square-foot preclinical research facility in San Diego, California.

Business Segment Analysis

Biologics and Drug Delivery

Financial Performance:

• Revenue: $19.0 million (+10% YoY)
• Operating Margin: Not disclosed at segment level.
• Key Growth Drivers: Increased demand for disposable products as multiple partners progress in their clinical trials. The segment's growth is highly dependent on partners' continued research, successful clinical trials, regulatory approvals, and commercialization of gene and cell therapies.

Product Portfolio:

• SmartFlow Neuro cannula: An MRI-compatible injection and aspiration cannula, used for direct brain delivery of gene and cell therapies. Received De Novo marketing authorization in 2024 for intraputaminal administration of eladocagene exuparvovec-tneq for AADC deficiency.
• Services: Preclinical development services (protocol consultation, study design and execution, in vivo biology services), clinical trial support, regulatory consultation, device development services, surgical workflow guidance, and translation services from preclinical to clinical settings.

Market Dynamics:

• The Company collaborates with over 60 pharma/biotech, academic, and contract research organization partners.
• These partnerships involve drug development programs at various stages, from preclinical research to late-stage regulatory trials, targeting rare single-gene pediatric disorders (e.g., AADC Deficiency, Friedreich’s Ataxia, Angelman Syndrome) and adult disorders (e.g., Parkinson’s disease, drug-resistant epilepsy, Huntington’s disease, Alzheimer’s disease, Glioblastoma).
• One pharmaceutical customer, PTC Therapeutics, Inc., accounted for approximately 15% of the segment's revenue in 2025.

Neurosurgery Navigation and Therapy

Financial Performance:

• Revenue: $14.8 million (+44% YoY)
• Operating Margin: Not disclosed at segment level.
• Key Growth Drivers: An increased customer base, additional revenues from the IRRA flow product (acquired in 2025), and higher sales from new offerings such as the SmartFrame OR Stereotactic System, ClearPoint Prism Neuro Laser Therapy System, and ClearPoint Navigation Software Version 3.0.

Product Portfolio:

• ClearPoint system: An integrated system of hardware, disposable components, and software for MRI-guided neurosurgical procedures (e.g., deep brain stimulation electrode placement, biopsy, laser catheter insertion, pharmaceutical infusion). Includes the ClearPoint Maestro Brain Model software for automated brain structure identification.
• SmartFrame Array Neuro Navigation System and Software: Enables operating room placement of the ClearPoint system with subsequent completion in the MRI suite.
• SmartFrame OR Stereotactic System: Allows for complete neurosurgical procedures to be performed in the operating room.
• ClearPoint Navigation Software Version 3.0: Supports end-to-end procedures in the operating room.
• ClearPoint Prism Neuro Laser Therapy System: A laser ablation system for necrotizing or coagulating soft tissue in neuro applications under MRI guidance, commercialized under exclusive global rights from CLS.
• IRRA flow Active Fluid Exchange System: (Acquired in 2025) Integrates continuous irrigation, drainage, and real-time intracranial pressure monitoring for intracranial fluid management in neurocritical care and operating room settings. Indicated for intracranial pressure monitoring and external drainage of intracranial fluid.

Market Dynamics:

• Electrode Placement: Addresses the market for Deep Brain Stimulation (DBS) and Responsive Neurostimulation (RNS) for conditions like Parkinson’s disease, essential tremor, and drug-resistant epilepsy. The ClearPoint system allows for intra-procedural navigation under general anesthesia.
• Laser Interstitial Thermal Therapy (LITT): Targets patients with primary and metastatic brain tumors and drug-resistant epilepsy.
• Brain Tumor Biopsy: Used for precise navigation to small, deep-seated brain tumors.
• Neurocritical Care: The IRRA flow system addresses conditions such as intraventricular hemorrhage, intracerebral hemorrhage, and subarachnoid hemorrhage, competing with traditional external ventricular drainage (EVD) systems. Potential future expanded indications include subdural hematomas, extended-duration infusions, oncology, and intracranial drug delivery.

Capital Equipment and Software

Financial Performance:

• Revenue: $3.1 million (-18% YoY)
• Operating Margin: Not disclosed at segment level.
• Key Growth Drivers: Revenue decreased in 2025 due to a decrease in the placements of ClearPoint navigation capital and software and Prism laser units. The Company's strategy is to leverage capital equipment sales to drive recurring, high-margin disposable product revenue.

Product Portfolio:

• ClearPoint reusable hardware: Head fixation frame, computer workstation, in-room monitor.
• ClearPoint software: ClearPoint system software, ClearPoint Maestro Brain Model.
• IRRA flow control unit: Reusable hardware component of the IRRA flow system.

Market Dynamics:

• Sales of capital equipment are strategic for establishing an installed base in hospitals, which then generates recurring revenue from disposable products. Hospital budgetary constraints can impact capital equipment purchases.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: In October 2025, 7,480 shares were surrendered to the Company at an average price of $26.11 per share, likely related to tax withholding on equity awards, not a formal repurchase program. The Company does not have any publicly announced repurchase plans or programs.
• Dividend Payments: ClearPoint Neuro, Inc. has never declared or paid cash dividends and does not anticipate doing so in the foreseeable future, intending to retain all future earnings for business operations and expansion.
• Future Capital Return Commitments: None explicitly disclosed.

Balance Sheet Position:

• Cash and Equivalents: $45.9 million (as of December 31, 2025)
• Total Debt: $50.9 million (aggregate principal amount of notes payable as of December 31, 2025)
• Net Cash Position: $(5.0) million
• Credit Rating: Not disclosed.
• Debt Maturity Profile: The notes payable under the 2025 Note Purchase Agreement mature on the sixth anniversary of their respective Purchase Dates, with scheduled principal payments of $50.9 million due in 2031.

Cash Flow Generation:

• Operating Cash Flow: $(23.9) million (2025)
• Free Cash Flow: $(24.4) million (calculated as Operating Cash Flow less Capital Expenditures)
• Cash Conversion Metrics: Not explicitly detailed in the filing.

Operational Excellence

Production & Service Model: ClearPoint Neuro, Inc. assembles its ClearPoint system and SmartFlow Neuro Cannula products at its Carlsbad, California facility using a combination of off-the-shelf and custom-made components from third-party suppliers. The ClearPoint Prism Neuro Laser Therapy System is manufactured exclusively by CLS. The reusable control unit and hardware for the IRRA flow system are manufactured at the Company's San Diego, California facility, while its disposables are sourced from third-party manufacturers. All internal manufacturing operations are performed in controlled environments, compliant with the FDA’s Quality Management System Regulation (QMSR), and the Company is certified to ISO 13485 and the Medical Device Single Audit Program (MDSAP). The Company's preclinical development services are conducted at its San Diego, California facility (ClearPoint Advanced Laboratories).

Supply Chain Architecture: Key Suppliers & Partners:

• Components (ClearPoint system): Primarily single-source suppliers for custom-made components due to quality, cost, and regulatory considerations, though alternative sources have been identified for certain components.
• ClearPoint Prism Neuro Laser Therapy System: CLS (exclusive manufacturer).
• IRRA flow disposables: Single-source third-party manufacturers with specialized expertise, operating under master service agreements. Alternative supply sources have been identified.
• Software: Licenses from third-party software providers are integrated into the Company's software products.

Facility Network:

• Corporate Headquarters: Solana Beach, California (7,500 sq ft leased).
• Manufacturing: Carlsbad, California (20,000 sq ft industrial building) and San Diego, California (21,200 sq ft, acquired with IRRAS).
• Research & Development: Solana Beach, California (personnel) and San Diego, California (30,000 sq ft, ClearPoint Advanced Laboratories).

Operational Metrics: No specific quantitative operational metrics such as capacity utilization or efficiency measures are disclosed in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: ClearPoint Neuro, Inc. markets and sells directly to physicians (neurosurgeons, neurologists) and hospitals for its neurosurgical applications. Following the IRRAS acquisition, the combined commercial organization also promotes the IRRA flow system directly to neurosurgeons, neuro-intensivists, critical care physicians, and hospital-based neurocritical care teams.
• Channel Partners: The Company has an exclusive global distribution agreement with CLS for the ClearPoint Prism Neuro Laser Therapy System.
• Digital Platforms: Not explicitly detailed as a primary distribution channel.

Customer Portfolio: Enterprise Customers:

• Customer Concentration: A small number of hospital customers account for a substantial portion of revenues from ClearPoint System and IRRA flow system products. The five largest hospital customers contributed approximately 21% of neurosurgery navigation disposable product revenues in 2025.
• Strategic Partnerships:
  • Biologics and Drug Delivery: Over 60 pharma/biotech, academic, and contract research organization partners utilize the Company's SmartFlow Neuro cannula and consulting services. PTC Therapeutics, Inc., a related party, accounted for approximately 15% of biologics and drug delivery revenues in 2025, under a supply agreement with minimum quarterly payments and regulatory support.
  • Technology & Development: Collaborations include Philips (for Philips Brain Model technology in ClearPoint Maestro Brain Model), UCB Biopharma SRL (multi-year license for gene therapy platforms), CLS (exclusive global commercialization rights for neurosurgical products), UCSF (license for SmartFlow Neuro cannula design features), and NE Scientific (development and license for GPU-accelerated software for brain therapy modeling).

Geographic Revenue Distribution: While the Company's operations and revenues are predominantly U.S.-based, it sells products in several countries outside the U.S. and holds international clearances for key therapy delivery products in 34 countries worldwide. The IRRA flow system also has CE mark certification in the European Union.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The medical device industry is highly competitive, characterized by rapid technological change and frequent new product introductions. The neurosurgical market is intensely competitive, dominated by a relatively small number of large companies with significant financial and human resources. The neurocritical care market, where the IRRA flow system competes, focuses on active management of intracranial fluid and pressure. The biologics and drug delivery market is a novel area, requiring expensive and time-consuming FDA-mandated clinical trials with uncertain commercial success.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Neurosurgery Navigation & Therapy:
  • Laser Ablation: Monteris Medical, Inc. (NeuroBlate system), Medtronic plc (Visualase system).
  • Conventional Stereotactic Neurosurgery: Brainlab AG, Medtronic plc, Elekta AB, FHC Inc., Integra LifeSciences Holdings Corporation, Neurologica Corporation (a subsidiary of Samsung Electronics Co.).
  • Robotic Systems: Zimmer Biomet Holdings, Inc. (ROSA® robot).
• Neurocritical Care (IRRA flow):
  • External Ventricular Drainage (EVD) systems: Medtronic plc, Spiegelberg GmbH & Co. KG, Sophysa, B. Braun, Integra LifeSciences.
• Biologics and Drug Delivery:
  • Image-guided drug delivery: Brainlab AG, Renishaw plc.
  • Preclinical Development Services: Clinical research organizations, government-funded non-profit entities, and industry experts.

Emerging Competitive Threats: New technologies, techniques, or products from competitors could offer superior price-performance combinations. Other medical device, biotechnology, and pharmaceutical companies with substantial resources may develop alternative navigation and therapy methods.

Competitive Response Strategy: ClearPoint Neuro, Inc. aims to maintain its competitive advantage through continuous research and development of new products and services, both independently and through third-party collaborations. This includes enhancing the IRRA flow system's workflow, expanding its labeling, and making design modifications to improve clinical use and adoption. The Company also seeks to anticipate changes in technology and market demand, and to leverage the integration of the IRRAS commercial team to increase commercial reach and scale across neurosurgical and neurocritical care customers.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• General Economic Conditions: Adverse impacts from inflation, higher interest rates, declining consumer/business confidence, supply chain disruptions, and potential recession, which could increase costs and reduce demand for products and services.
• Technology Disruption: Risk of new technologies or products from competitors offering better price-performance combinations, potentially rendering current products obsolete.
• Customer Concentration: Significant reliance on a small number of hospital customers (21% of neurosurgery navigation disposable revenue from top five) and one pharmaceutical customer (15% of biologics and drug delivery revenue), making the Company vulnerable to changes in their purchasing policies or financial difficulties.
• Market Adoption: ClearPoint system and IRRA flow system may not achieve broad market adoption due to physician familiarity with existing methods, lack of training exposure, perceived insufficient clinical benefits, hospital budgetary constraints, pricing of disposables, and the need for additional clinical data.
• Drug Delivery Dependence: Revenue prospects are highly dependent on maintaining relationships with drug delivery customers and their success in preclinical studies, clinical trials, regulatory approvals, and commercialization of gene and cell therapies.
• Market Size Estimates: Estimates of the total addressable market for products and services may be smaller than anticipated, impairing prospective market and revenue opportunities.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Supplier Dependency: Reliance on single facilities for manufacturing and services (Carlsbad and San Diego, California) and single-source suppliers for many components and finished products (e.g., IRRA flow disposables, ClearPoint Prism Neuro Laser Therapy System from CLS), exposing the Company to significant disruption risks from natural disasters, power outages, or supplier issues.
• Geographic Concentration: Manufacturing and R&D facilities are located in Southern California, a seismically active area prone to earthquakes and wildfires, increasing the risk of operational interruptions.
• Hazardous Materials: Use of hazardous materials in manufacturing and services exposes the Company to health, safety, environmental, and regulatory risks, including potential for incidents, compliance costs, and liabilities.

Financial & Regulatory Risks

Market & Financial Risks:

• Demand Volatility: Revenue can be meaningfully impacted by changes in customer research and development plans or clinical trial outcomes.
• Foreign Exchange: Exposure to fluctuations in exchange rates for international sales.
• Credit & Liquidity: History of net losses and cumulative deficit ($216.9 million as of December 31, 2025). Significant debt ($50.9 million outstanding as of December 31, 2025) with covenants that restrict operational and financial flexibility. Uncertainty in raising additional capital on acceptable terms, which could delay or eliminate business activities. Cash and cash equivalents are subject to economic risk, and assets held at financial institutions may exceed FDIC insurance coverage.
• Reimbursement: Inadequate coverage and reimbursement from third-party payors for procedures utilizing the Company's products could adversely affect product adoption, revenues, and profitability.

Regulatory & Compliance Risks:

• Industry Regulation: Extensive regulation by the FDA and foreign authorities (e.g., 510(k), PMA, De Novo, QMSR, Medical Device Reporting, EU MDR). Failure to comply can result in fines, injunctions, recalls, and other penalties.
• Export Controls: Subject to export restrictions and controls related to technology.
• Data Privacy: Compliance with federal and state laws (e.g., HIPAA, CCPA, CPRA) and international regulations (e.g., GDPR) protecting personal information. Non-compliance could lead to penalties and reputational damage.
• Off-label Promotion: Risk of significant liability if promotional activities are deemed to promote unapproved or off-label uses of products.
• Clinical Evidence: Limitations in existing clinical evidence for the IRRA flow system may hinder clinical and commercial adoption, potentially requiring further costly and time-consuming studies.
• Government Shutdown: Federal government shutdowns could materially delay or disrupt FDA review and approval processes, impacting product commercialization and customer programs.

Geopolitical & External Risks

Geopolitical Exposure: Global economic conditions and geopolitical instability (e.g., conflicts in Ukraine, Middle East, Asia-Pacific tensions) can interfere with supply chains, manufacturing costs, access to raw materials, and customer relationships. Shifts in trade, economic, and regulatory policies may also increase costs or limit international business expansion.

Innovation & Technology Leadership

Research & Development Focus: ClearPoint Neuro, Inc.'s R&D efforts are focused on expanding its technological platforms across neurosurgery, neurocritical care, and biologics/drug delivery. Core Technology Areas:

• MRI-guided Interventions: Foundational capability for the ClearPoint system.
• Operating Room Neurosurgical Devices: Development of systems like SmartFrame OR Stereotactic System and ClearPoint Navigation Software Version 3.0 for end-to-end OR procedures.
• Neurocritical Care: Enhancements to the IRRA flow system's workflow, labeling expansion, and potential design modifications to improve clinical use and adoption.
• Biologics and Drug Delivery: Continued development of delivery devices and services for gene and cell therapies into the central nervous system, utilizing the SmartFlow Neuro cannula.
• Laser Therapy: Commercialization and expansion of the ClearPoint Prism Neuro Laser Therapy System.
• Software: Development of advanced software tools like ClearPoint Maestro Brain Model (licensed from Philips) for automated brain structure identification and NE Scientific’s GPU-accelerated software for therapy modeling. Innovation Pipeline: The Company is developing a proprietary robotic neuro-navigation system.

Intellectual Property Portfolio:

• Patent Strategy: ClearPoint Neuro, Inc. owns or licenses over 130 issued patents in neurosurgical and MRI-guided interventions, with the IRRAS acquisition adding ten patent families in fluid exchange systems and neuromonitoring. The Company seeks patent protection in the U.S. and internationally.
• Licensing Programs: The Company has various licensing agreements, including with Philips (for Philips Brain Model technology), UCB Biopharma SRL (for gene therapy platforms), CLS (exclusive global commercialization rights for neurosurgical products), UCSF (for SmartFlow Neuro cannula design features), and NE Scientific (for GPU-accelerated software).
• IP Litigation: The medical device industry is prone to extensive intellectual property litigation, which could result in costly disputes, substantial damages, or restrictions on product sales.

Technology Partnerships: Key technology partnerships include collaborations with Philips for brain modeling software, UCB Biopharma SRL for gene therapy delivery platforms, CLS for laser therapy system development and manufacturing, UCSF for cannula design, and NE Scientific for advanced software solutions.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The Company's future success depends on its ability to attract, retain, and motivate highly skilled personnel, particularly in sales, clinical support, product development, and marketing. All employees, including senior management, are at-will.

Board Composition: The Board of Directors has adopted a Code of Business Conduct and Ethics, applicable to all employees, officers, agents, representatives, directors, and consultants.

Human Capital Strategy

Workforce Composition: As of March 6, 2026, ClearPoint Neuro, Inc. had 172 full-time employees, including 37 from the IRRAS acquisition.

Talent Management: Acquisition & Retention: The Company prioritizes cultural fit and energy in recruiting, assessing candidates' potential contributions beyond specific tasks. It aims to provide market-based compensation to retain employees. Diversity & Development: New employees receive industry-relevant compliance training and are introduced to the Code of Business Conduct and Ethics. No specific diversity metrics or formal development programs are disclosed.

Environmental & Social Impact

Environmental Commitments: No specific environmental commitments, emissions targets, carbon neutrality goals, or renewable energy strategies are explicitly disclosed in the filing.

Supply Chain Sustainability: No specific supplier engagement programs for ESG or responsible sourcing initiatives are explicitly disclosed.

Social Impact Initiatives: The Company's products and services contribute to the development of treatments for rare single-gene pediatric disorders (e.g., AADC Deficiency, Friedreich’s Ataxia, Angelman Syndrome) and adult neurological disorders (e.g., Parkinson’s disease, drug-resistant epilepsy, Huntington’s disease, Alzheimer’s disease, Glioblastoma), implying a positive social impact through advancing medical therapies.

Business Cyclicality & Seasonality

Demand Patterns: The Company's business is sensitive to macroeconomic trends, including inflationary pressures, changes in monetary policy, and declining consumer confidence, which can reduce demand for products and services. Economic uncertainty, elevated unemployment, and rising healthcare costs may lead to fewer elective or advanced medical treatments, impacting procedure volumes. The development of gene and cell therapies by customers is inherently risky, complex, costly, and uncertain, affecting demand for the Company's drug delivery products and services.

Planning & Forecasting: ClearPoint Neuro, Inc.'s plans for the next twelve months anticipate increased revenues from hardware and disposable product sales, driven by greater utilization of the ClearPoint system and IRRA flow system at existing sites, and new installations. The Company also expects continued payments from strategic partnerships, consulting services, and sales to pharmaceutical partners for gene and stem cell therapy trials.

Regulatory Environment & Compliance

Regulatory Framework: ClearPoint Neuro, Inc. operates in a highly regulated industry, subject to extensive oversight by the FDA in the U.S. and various foreign governmental authorities. Industry-Specific Regulations:

• Medical Devices: Compliance with the Federal Food, Drug, and Cosmetic Act (FDCA), including 510(k) clearance, De Novo classification, Premarket Approval (PMA), Quality Management System Regulation (QMSR), Medical Device Reporting, and regulations for advertising and promotion. International compliance includes CE marking and the European Medical Device Regulation (EU MDR).
• Preclinical Services: Adherence to the Animal Welfare Act (AWA) and Good Laboratory Practice (GLP) regulations for research involving animals.
• Healthcare Laws: Compliance with federal and state healthcare fraud and abuse laws, including the Anti-Kickback Statute, False Claims Act, and HIPAA, as well as the Foreign Corrupt Practices Act (FCPA) for international operations.
• Data Privacy: Subject to federal and state data privacy laws (e.g., HIPAA, California Consumer Privacy Act, California Privacy Rights Act) and international regulations like the EU General Data Protection Regulation (GDPR). Trade & Export Controls: The Company is subject to export restrictions and controls related to technology and must comply with U.S. laws like the FCPA for international business practices. Legal Proceedings: As of the filing date, there are no material pending legal proceedings. A previously disclosed patient lawsuit was settled in August 2025, with the settlement covered by insurance and having no material impact on financial statements.

Tax Strategy & Considerations

Tax Profile: ClearPoint Neuro, Inc. reported an effective tax rate of -0.2% for 2025. The Company has net operating loss (NOL) carryforwards of approximately $258.2 million for federal and $163.1 million for state income tax purposes as of December 31, 2025. Federal NOLs begin expiring in 2026, and state NOLs in 2028. The Company's ability to utilize these NOLs may be limited by "ownership change" rules under Section 382 of the Internal Revenue Code. A valuation allowance of $64.2 million has been established against deferred tax assets due to uncertainties regarding their realization. The Company is subject to multiple state minimum income tax expenses. Tax Reform Impact: The Inflation Reduction Act (IRA) and the One Big Beautiful Bill Act are noted for their potential impacts on pharmaceutical and biotech R&D spending and Medicaid funding, which could indirectly affect the Company's business.

Insurance & Risk Transfer

Risk Management Framework: ClearPoint Neuro, Inc. maintains liability insurance and business interruption insurance, which it believes to be appropriate for its industry. However, this coverage is subject to deductibles and limitations and may not be adequate for all future claims or available on commercially reasonable terms. Insurance related to information risks, breaches, and business interruption also has deductibles and coverage limitations. No other specific risk transfer mechanisms are explicitly detailed.